Cyclerion Therapeutics Announces Topline Phase 2 Results for sGC Stimulator Praliciguat in Heart Failure with Preserved Ejection Fraction (HFpEF)
– Study in HFpEF patients did not meet primary endpoint; company discontinuing development of praliciguat in HFpEF –
– Conference call to be held at 8:30 a.m. ET today –
The study did not meet statistical significance on its primary endpoint of improved exercise capacity from baseline as compared to placebo, measured by cardiopulmonary exercise testing (CPET). There was clear evidence of drug exposure and pharmacological activity as judged by expected reductions in blood pressure. Praliciguat was generally well tolerated, and the safety profile supported investigation of praliciguat in other indications. While there were no trends observed in improving HFpEF symptoms, a positive trend in reducing HbA1c levels was observed in the subset of patients with diabetes. This is consistent with the results observed in the company’s Phase 2 study of praliciguat in diabetic nephropathy, which were also reported today.
Cyclerion is discontinuing development of praliciguat in HFpEF. Full results from the study will be presented at a future medical meeting.
“CAPACITY-HFpEF had an innovative design, focused on those patients we believed were more likely to respond to therapy. While we are disappointed with the study results, particularly given the unmet need in HFpEF, we are very grateful to the patients who participated, as well as the physicians, other study staff and our internal teams who ran a high-quality trial that enabled us to arrive at a clear result for this indication,” said
With its praliciguat Phase 2 studies completed, Cyclerion intends to focus its investments on near-term value-creation opportunities – including out-licensing praliciguat for diabetic nephropathy, advancing its STRONG SCD Phase 2 study of olinciguat in sickle cell disease, its Phase 1 study of IW-6463 for central nervous system disorders, as well as ongoing innovation – and to reduce its monthly cash expenses by 25%. As of
About Praliciguat Phase 2 Study in HFpEF (CAPACITY)
The CAPACITY study, a randomized, placebo-controlled Phase 2 study, evaluated the safety and efficacy of once-daily praliciguat 40 mg or placebo in 196 patients with HFpEF over a 12-week period. Participating patients were 45 years or older and had HFpEF with an ejection fracture greater than or equal to 40%. The primary measure of efficacy was change in exercise tolerance, as assessed by cardiopulmonary exercise testing (CPET). No statistically significant effects were observed.
Praliciguat was generally well tolerated in this study. The most common adverse events (AEs) reported in patients treated with praliciguat in this study were headache, dizziness, urinary tract infection and hypotension. The frequency of AEs and serious AEs were similar between the treatment and placebo groups. Discontinuations due to AEs were 4.8% of praliciguat-treated patients compared to 3.3% of placebo-treated patients.
Conference Call Information
Cyclerion will host a conference call and live audio webcast today at
The call will be available for replay via telephone starting
Forward Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements about our intentions to out-license praliciguat and advance our clinical trials; the progression of our discovery programs into clinical development; our business and operations; ; and our sufficiency of cash. We may, in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include those related to the possibility that we may not achieve the expected benefits of the separation from Ironwood, and that this separation could harm our business, results of operations and financial condition; the risk that we may be unable to make, on a timely or cost-effective basis, the changes necessary to operate as an independent company; the risk of cessation or delay of any of the ongoing or planned clinical studies and/or our development of our product candidates; the risk of a delay in the enrollment of patients in our clinical studies; the risk that any one or more of our product candidates will not be successfully developed, approved or commercialized; our lack of independent operating history and the risk that our accounting and other management systems may not be prepared to meet the financial reporting and other requirements of operating as an independent public company; the risk that the separation from Ironwood may adversely impact our ability to attract or retain key personnel; our risk that our estimates regarding our use of cash may prove inaccurate; and the other risks and uncertainties listed under the “Risk Factors” section and elsewhere in our Registration Statement on Form S-1 filed on
Source: Cyclerion Therapeutics, Inc.